Terms: = Testicular cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Prognosis
670 results:
1. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract] [Full Text] [Related]
2. New insights on testicular cancer prevalence with novel diagnostic biomarkers and therapeutic approaches.
Sadek KM; AbdEllatief HY; Mahmoud SFE; Alexiou A; Papadakis M; Al-Hajeili M; Saad HM; Batiha GE
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2052. PubMed ID: 38507271
[TBL] [Abstract] [Full Text] [Related]
3. Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses.
Sköld C; Jansson AK; Glimelius I
J Intern Med; 2024 Jun; 295(6):715-734. PubMed ID: 38468475
[TBL] [Abstract] [Full Text] [Related]
4. Review on Sertoli-Leydig Cell Tumours of the Ovary.
Muscat C; Calleja-Agius J
Discov Med; 2024 Feb; 36(181):234-247. PubMed ID: 38409829
[TBL] [Abstract] [Full Text] [Related]
5. Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
Incesu RB; Barletta F; Tappero S; Piccinelli ML; Garcia CC; Morra S; Scheipner L; Tian Z; Saad F; Shariat SF; Ahyai S; Longo N; Chun FKH; de Cobelli O; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Cancer Epidemiol; 2024 Apr; 89():102538. PubMed ID: 38377946
[TBL] [Abstract] [Full Text] [Related]
6. Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins.
Spinos T; Zografos E; Koutsoukos K; Zagouri F; Kosmas C; Driva TS; Goutas D; Gakiopoulou C; Agrogiannis G; Theochari E; Tzavara C; Lazaris AC
Int Urol Nephrol; 2024 Jun; 56(6):1887-1898. PubMed ID: 38285100
[TBL] [Abstract] [Full Text] [Related]
7. Oncological and endocrinological outcomes for children and adolescents with testicular and ovarian sex cord-stromal tumors. Results of the TGM13 National Registry.
Fuentes C; Ouldbey Y; Orbach D; Sudour-Bonnange H; Verité C; Rome A; Dumesnil C; Thebaud E; Hameury F; Dijoud F; Chabaud S; Cote MD; Fresneau B; Faure-Conter C
Pediatr Blood Cancer; 2024 Apr; 71(4):e30864. PubMed ID: 38259036
[TBL] [Abstract] [Full Text] [Related]
8. Urological cancers and ChatGPT: Assessing the Quality of Information and Possible Risks for Patients.
Ozgor F; Caglar U; Halis A; Cakir H; Aksu UC; Ayranci A; Sarilar O
Clin Genitourin Cancer; 2024 Apr; 22(2):454-457.e4. PubMed ID: 38246831
[TBL] [Abstract] [Full Text] [Related]
9. Epidemiology, Management, and Survival Outcomes of Germ Cell cancer in Southern Portugal: A Population-Based Study (2008-2012).
Brito M; Ramos M; Silva JP; Câmara G; Mayer A; Miranda A; Coelho JLP; Moreira A; Esteves S
Clin Genitourin Cancer; 2024 Feb; 22(1):e170-e177.e1. PubMed ID: 38061978
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology testicular cancer Guidelines Panel and Guidelines Office.
Boormans JL; Sylvester R; Anson-Cartwright L; Glicksman RM; Hamilton RJ; Hahn E; Daugaard G; Lauritsen J; Wagner T; Avuzzi B; Nicolai N; Del Muro XG; Aparicio J; Stalder O; Rothermundt C; Fischer S; Laguna MP
Eur Urol Oncol; 2024 Jun; 7(3):537-543. PubMed ID: 37951820
[TBL] [Abstract] [Full Text] [Related]
11. Pediatric Sertoli-Leydig Cell Tumors of the Ovary: An Integrated Study of Clinicopathological Features, Pan-cancer-Targeted Next-generation Sequencing and Chromosomal Microarray Analysis From a Single Institution.
Yang B; Chour W; Salazar CG; Zamiara P; Schmidt RJ; Raca G; Shillingford N; Zhou S; Warren M; Parham DM; Pawel B; Wang LL
Am J Surg Pathol; 2024 Feb; 48(2):194-203. PubMed ID: 37946548
[TBL] [Abstract] [Full Text] [Related]
12. Sertoli-Leydig cell tumor: a clinicopathological analysis in a comprehensive, national cohort.
Bekker P; Miland-Samuelsen AR; Smerdel MP; Schnack TH; Lauszus FF; Karstensen SH
Int J Gynecol Cancer; 2023 Dec; 33(12):1921-1927. PubMed ID: 37907261
[TBL] [Abstract] [Full Text] [Related]
13. Origin and outcome of metastatic tumours to the testes: a nationwide study.
Woortman C; van Leenders GJLH; Hugen N; van Oijen MGH; Nagtegaal ID
BJU Int; 2024 Mar; 133(3):305-313. PubMed ID: 37877215
[TBL] [Abstract] [Full Text] [Related]
14. [
Lee K; Kim YI; Oh JS; Seo SY; Yun JK; Lee GD; Choi S; Kim HR; Kim YH; Kim DK; Park SI; Ryu JS
Sci Rep; 2023 Oct; 13(1):17619. PubMed ID: 37848723
[TBL] [Abstract] [Full Text] [Related]
15. Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
Lauritsen J; Sauvé N; Tryakin A; Jiang DM; Huddart R; Heng DYC; Terbuch A; Winquist E; Chovanec M; Hentrich M; Fankhauser CD; Shamash J; Del Muro XG; Vaughn D; Heidenreich A; Sternberg CN; Sweeney C; Necchi A; Bokemeyer C; Bandak M; Jandari A; Collette L; Gillessen S; Beyer J; Daugaard G
Br J Cancer; 2023 Nov; 129(11):1759-1765. PubMed ID: 37777577
[TBL] [Abstract] [Full Text] [Related]
16. Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors.
Takami H; Satomi K; Fukuoka K; Nakamura T; Tanaka S; Mukasa A; Saito N; Suzuki T; Yanagisawa T; Sugiyama K; Kanamori M; Kumabe T; Tominaga T; Tamura K; Maehara T; Nonaka M; Asai A; Yokogami K; Takeshima H; Iuchi T; Kobayashi K; Yoshimoto K; Sakai K; Nakazato Y; Matsutani M; Nagane M; Nishikawa R; Ichimura K
Sci Rep; 2023 Sep; 13(1):15760. PubMed ID: 37735187
[TBL] [Abstract] [Full Text] [Related]
17. Excellent survival in relapsed stage I testicular cancer.
Speicher P; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Beyer J; Akhoundova D
BMC Cancer; 2023 Sep; 23(1):870. PubMed ID: 37715132
[TBL] [Abstract] [Full Text] [Related]
18. Dose comparison of robustly optimized intensity modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for testicular seminoma.
Rønde HS; Kronborg C; Høyer M; Hansen J; Bak ME; Agergaard SN; Als AB; Agerbæk M; Lauritsen J; Meidahl Petersen P; Dysager L; Kallehauge JF
Acta Oncol; 2023 Oct; 62(10):1222-1229. PubMed ID: 37683054
[TBL] [Abstract] [Full Text] [Related]
19. Conditional survival of stage III non-seminoma testis cancer patients.
Incesu RB; Barletta F; Tappero S; Morra S; Garcia CC; Scheipner L; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Ahyai S; Chun FKH; Longo N; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Urol Oncol; 2023 Oct; 41(10):435.e11-435.e18. PubMed ID: 37558516
[TBL] [Abstract] [Full Text] [Related]
20. Identification of risk factors and prediction models for secondary malignant neoplasms (SMNs)-free survival and SMNs-specific survival in testicular cancer survivors.
Fu H; Talluri S; Rai S; Liang L; Trivedi J; Ankem MK
World J Urol; 2023 Sep; 41(9):2413-2420. PubMed ID: 37530808
[TBL] [Abstract] [Full Text] [Related]
[Next]
